Shield Therapeutics PLC Grant of Share Awards (6727J)

TIDMSTX TIDMSTXW

RNS Number : 6727J

Shield Therapeutics PLC

13 September 2016

Shield Therapeutics plc

("Shield" or the "Company")

Grant of Share Awards

London, UK, 13(th) September 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that, following approval at the AGM on 4(th) August 2016, it has granted awards in the form of options over ordinary shares in the capital of the Company ("Award Shares") to the following executives under its Long Term Incentive Plan ("LTIP").

   Carl Sterritt:                                       Director                               92,767 
   Richard Jones:                                   Director                               67,610 
   Paul Steckler                                      PDMR                                  58,176 
   Angela Hildreth                                 PDMR                                  34,591 

In total awards have now been granted over 2,026,725 shares under the LTIP. The exercise price per Award Share is 1.5 pence and awards are exercisable between February 2019 and February 2026, subject to applicable performance conditions having been satisfied. The grant of awards is part of the Company's long-term incentive arrangements designed to directly align the interest of the shareholders and executives.

The Company's LTIP was adopted by the Board on 12th February 2016. The LTIP provides for awards of ordinary shares to be made to eligible employees. The arrangements are described more fully in the Admission Document, a copy of which is available on the Company's website (www.shieldtherapeutics.com).

-Ends-

For further information please contact:

 
 Shield Therapeutics plc                [phone] 
 Carl Sterritt, Chief Executive 
  Officer 
  Richard Jones, Chief Financial 
  Officer 
 
 Nominated Adviser and Sole 
  Broker 
  Liberum Capital Limited 
  Christopher Britton 
  Steve Pearce 
  Jamil Miah                            [phone] 
 
 Financial PR Advisor                   [phone] 
  Consilium Strategic Communications     [e-mail] 
 Mary-Jane Elliott 
  Matthew Neal 
  Lindsey Neville 
  Hendrik Thys 
 

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Company has a marketed product, Feraccru(R), for the treatment of iron deficiency anaemia (IDA) which has exclusive IP rights until 2034. In addition, the Company is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ------------------------------------------------------------------ 
 a)   Name                       Carl Sterritt: Director / PDMR 
                                  Richard Jones: Director / PDMR 
                                  Paul Steckler PDMR 
                                  Angela Hildreth PDMR 
---  -------------------------  --------------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------------ 
 a)   Position/status            All PDMRs of Shield Therapeutics 
---  -------------------------  --------------------------------------- 
 b)   Initial                    Initial Notification 
       notification/ 
       Amendment 
---  -------------------------  --------------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, 
       auctioneer or auction monitor 
---  ------------------------------------------------------------------ 
 a)   Name                       Shield Therapeutics plc 
---  -------------------------  --------------------------------------- 
 b)   LEI                        n/a 
---  -------------------------  --------------------------------------- 
 4    Details of the transaction(s): section 
       to be repeated for (i) each type of 
       instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place 
       where transactions have been conducted 
---  ------------------------------------------------------------------ 
 a)   Description                Option over ordinary shares 
       of the                     of 1.5p each in the capital 
       financial                  of the Company 
       instrument, 
       type of 
       instrument 
 
 
 
       Identification             ISIN of Ordinary Shares: GB00BYV81293 
       code 
---  -------------------------  --------------------------------------- 
 b)   Nature                     Grant of Options over ordinary 
       of the                     shares in accordance with the 
       transaction                Company's Long Term Incentive 
                                  Plan 
---  -------------------------  --------------------------------------- 
 c)   Price(s)                   Exercise price: 1.5p 
       and volume(s) 
                                  Volumes: 
                                  Carl Sterritt: 92,767 
                                  Richard Jones: 67,610 
                                  Paul Steckler 58,176 
                                  Angela Hildreth 34,591 
---  -------------------------  --------------------------------------- 
 d)   Aggregated 
       information 
 
        *    Aggregated volume     253,144 
 
 
                                   Exercise price: 1.5p 
        *    Price 
---  -------------------------  --------------------------------------- 
 e)   Date of                    12 September 2016 
       the transaction 
---  -------------------------  --------------------------------------- 
 f)   Place                      Outside a trading venue 
       of the 
       transaction 
---  -------------------------  --------------------------------------- 
 

Name of authorised official of issuer responsible for making notification.

Richard Jones

CFO and Company Secretary to Shield Therapeutics plc

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLJMPTMBTBMBF

(END) Dow Jones Newswires

September 13, 2016 04:25 ET (08:25 GMT)